Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Higher Kingston, United Kingdom Clinical Trials

A listing of Higher Kingston, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (71) clinical trials

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

This is an open-label, randomized, parallel group two-stage phase 1-2 study with an escalation and an expansion component. This study will evaluate an extended-release (ER) formulation of onapristone in patients with prostate cancer in which Progesterone Receptor (PR) may be contributing to tumor progression. A companion diagnostic to select patients …

Phase

5.79 miles

Learn More »

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. …

Phase

5.79 miles

Learn More »

A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)

PARC is an international phase I/II trial evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). Currently the outcomes for these patients are poor and the therapeutic options are limited with a …

Phase

5.79 miles

Learn More »

GEN1029 (HexaBody -DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

The trial is an open-label, multi-center safety trial of GEN1029 (HexaBody-DR5/DR5). The trial consists of two parts a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Phase

5.79 miles

Learn More »

GEN3013 (DuoBody -CD3xCD20) Safety Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part (phase 1, first-in-human (FIH) and an expansion part phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Phase

5.79 miles

Learn More »

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

The first molecular profiling protocols have been launched in Europe (MOSCATO-01 (Geoerger 2014), MAPPYACTS, INFORM, iTHER, SM-PAEDS, etc.) determining multiple actionable alterations in pediatric recurrent cancers. Increasingly, stratified approaches are being implemented to enrich clinical trials of molecularly targeted agents and possibly improve outcomes in specific populations i.e. a molecularly …

Phase

5.79 miles

Learn More »

Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their …

Phase

5.79 miles

Learn More »

GEN1042 Safety Trial in Subjects With Malignant Solid Tumors

The trial is an open-label, multi-center, safety trial of GEN1042. The trial consists of two parts, a dose escalation (phase 1, first-in-human (FIH) and an expansion part (Phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Phase

5.79 miles

Learn More »

A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has …

Phase

6.47 miles

Learn More »

Study to Evaluate CCS1477 in Advanced Tumours

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer (mCRPC) or advanced solid tumours.

Phase

6.47 miles

Learn More »